Les Hopitaux Universitaires De Strasbourg — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

11 Recruiting

3 Completed trials

2 Countries active

59 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III/IV

Phase IV

Phase III: 6 Phase II/III: 2 Phase II: 4 Phase III/IV: 2 Phase IV: 3

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Intracranial aneurysm 1 Relapsing-remitting multiple sclerosis 1

Top IMPs

HUMAN NORMAL IMMUNOGLOBULIN 2 AZATHIOPRINE 1 CICLOSPORIN 1 DIMETHYL FUMARATE 1 DIROXIMEL FUMARATE 1 DORNASE ALFA 1 EVEROLIMUS 1 GLATIRAMER ACETATE 1 HYDROCORTISONE 1 HYDROXYCARBAMIDE 1 INTERFERON BETA-1A 1 IODIXANOL 1

All trials

17 total

A prospective, randomized, and controlled study comparing two treatment strategies (Dose REduction of Antipsychotics vs. Maintenance treatme… Pending

2023-509558-80-00 Phase III 1 country
Retinoic acid and sperm production in infertile men Pending

2024-519644-33-00 Phase II 1 country ISOTRETINOIN
Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angio… Pending

2025-524884-18-01 Phase III 1 country IODIXANOL
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting

2024-518493-14-00 Phase II/III 1 country AZATHIOPRINE; CICLOSPORIN; EVEROLIMUS; HYDROCORTISONE; METHYLPREDNISOLONE HYDROG…
Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf… Recruiting

2024-519991-18-00 Phase IV 1 country
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting

2024-513475-41-00 Phase III 1 country DIMETHYL FUMARATE; DIROXIMEL FUMARATE; GLATIRAMER ACETATE; INTERFERON BETA-1A; P…
TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS) Recruiting

2024-517845-14-00 Phase II 1 country TESTOSTERONE UNDECANOATE
EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized… Recruiting

2024-516902-46-00 Phase II/III 1 country METHYLPHENIDATE HYDROCHLORIDE
HyperChrono Recruiting

2023-506663-33-00 Phase II 1 country MELATONIN
PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting

2023-508531-30-00 Phase II 1 country TRAMETINIB; VINBLASTINE SULFATE
Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An… Recruiting

2024-515243-37-00 Phase III/IV 1 country HUMAN NORMAL IMMUNOGLOBULIN
Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on inci… Recruiting

2024-515075-36-00 Phase IV 1 country
TRAUMADORNASE A Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce th… Recruiting

2024-512034-14-00 Phase III 1 country DORNASE ALFA
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Phase III/IV 1 country
Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up Ended

2024-515562-14-00 Phase IV 1 country HYDROXYCARBAMIDE
A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTH… Ended

2024-516884-10-00 Phase III 2 countries SPIRONOLACTONE
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended

2024-517309-95-00 Phase III 1 country HUMAN NORMAL IMMUNOGLOBULIN

Showing 1–17 of 17 trials

← All sponsors A–Z